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Abstract 
Title Page  
Jeremy Martinson, DPhil 
 
The Influence of Single Nucleotide Polymorphisms and Epigenetics on HIV Disease 
Progression 
Jenna Malinauskas, MS 
University of Pittsburgh, 2018 
Abstract 
Human immunodeficiency virus (HIV) is one of the most significant public health issues globally, 
however; little is known about the factors contributing to the rate of AIDS progression. Due to 
antiretroviral therapy, disease progression classification can no longer be attained, therefore; 
retrospective samples from the Multicenter AIDS Cohort Study (MACS) are used to study host 
genetic factors contributing to progression though studying Nonprogressors (NPs) and Progressors 
(PRs). The genetic response to HIV infection can be influenced by polymorphisms, or epigenetic 
factors such as chromatin accessibility. Using previously acquired microarray data, we observe 
multiple genes differentially regulated when comparing immature dendritic cells (iDCs) from NPs 
and PRs, and recent studies by Rappocciolo et al, 2014 demonstrate that iDCs from NPs have 
inefficient trans-infection due to reduced cellular cholesterol. I hypothesize that sequence variation 
and/or epigenetic regulation may be influencing these processes and contributing to slower disease 
progression. 
Next generation sequencing was used to determine whether SNPs in the promoter regions 
of palladin, contribute to differential gene expression. Assay for transposase chromatin 
accessibility (ATAC-seq) was validated for use on MACS samples to determine if chromatin 
accessibility differs between NPs and PRs. 
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Promoter region sequencing results demonstrate a variant within palladin with an allele 
frequency of 0.929 in the NP cohort near the promoter region of isoform 4. The variant is absent 
in the PR cohort and is located within the transcription factor binding site for RB1. RB1 controls 
heterochromatin structure contributing to gene expression, therefore; a variant within the binding 
site may influence isoform 4 expression in NPs. 
ATAC-sequencing results indicate successful sequencing of healthy donor iDCs using the 
Omni-ATAC-seq protocol described by Corces, et al, 2018. Library complexity, sequencing depth 
and coverage were acceptable when analyzed with ATACseqQC. These results suggest that the 
Omni-ATAC-seq method can successfully be used on MACS cohort samples to determine 
differences in chromatin accessibility between NPs and PRs. 
Public Health Significance: Understanding how host genetics influence disease 
progression to AIDS is important for the development of new therapies. Additionally, we are 
discovering novel innate mechanisms of infectious disease control that may be applicable to viral 
infections broadly.  
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1.0 Introduction 
Human Immunodeficiency Virus (HIV), the causal agent of Acquired Immune Deficiency 
Syndrome (AIDS) was discovered in the early 1980s after five homosexual men from Los Angeles 
suffered from Pneumocystis carinii pneumonia (PCP) (1). This previously unknown illness was 
characterized by sexual transmission, opportunistic infections, and a rare type form of cancer 
known as Kaposi’s sarcoma (2). By 1983, HIV was determined as the causative agent, and in 1984 
the Multicenter AIDS Cohort Study was initiated with a goal of studying HIV pathogenesis as well 
as disease progression (3). Since the early years of HIV/AIDS, advances such as combined 
antiretroviral therapy (cART) and pre-exposure prophylaxis (PrEP) have greatly improve clinical 
outcomes for those infected with HIV-1 and those who are at high risk, however; a cure remains 
elusive (4, 5). Like many diseases, HIV-1 infection outcomes are influenced by the host response 
to infection, with some individuals possessing an inherent ability to control their infection in the 
absence of therapy (6). Studying these rare individuals may shed new light on HIV-1 therapy and 
treatment while simultaneously identifying novel mechanisms of viral control.   
1.1 Natural History of HIV Infection 
In 2014, the CDC revised the case definition for HIV-1 infection in the United States and 
divided the stages of disease into five categories based on the CD4+ T cell count. Stage 0 is defined 
by a negative HIV-1 test result within 6 months of acquiring a positive HIV-1 diagnosis. An 
individual is at Stage 1 when it has been 6 months since their positive HIV-1 diagnosis and CD4+ 
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T cell counts are greater than or equal to 500 cells/µL of plasma. Stage 2 is defined by CD4+ T 
cell counts between 200-499/µL of plasma, and less than 200 cells/µL of plasma is considered 
Stage 3 which is often accompanied by an opportunistic infection due to immunodeficiency. The 
fourth stage of HIV-1 infection is “unknown” classified by an unknown CD4+ T cell count and T 
cell percentage in which case the stage of HIV-1 infection is undetermined (7). While disease 
progression and symptoms can vary, acute viremia at Stage 0 can result in flu-like symptoms 
including; headache, fever, and myalgia. Simultaneously, viral titers in the plasma increase, CD4+ 
T cells counts decline and a vigorous CD8+ T cell response develops leading to the resolution of 
acute infection symptoms.  Following the acute phase of infection, the chronic phase begins about 
three to four months later resulting in suppressed viral titer, and a slow decline in CD4+ T cells 
eventually leading to the development of AIDS at Stage 3 (8).  
1.2 HIV Pathogenesis 
HIV-1 is often acquired via transmission at mucosal surfaces such as vaginal, rectal, penile, 
and rarely oral transmission (9-12). Once transmitted, the virus typically binds to cells expressing 
the primary receptor molecule CD4; primarily CD4+ T cells, macrophages and monocytes. Viral 
entry is achieved via the interaction of viral proteins gp120 and gp41 with the human secondary 
receptor proteins CCR5 and CXCR4 (13). Upon entry, the virus disassembles releasing two copies 
of the single-stranded RNA genome, and the viral proteins; reverse transcriptase (RT), integrase 
(IN) and protease (PR).  Viral RNA becomes reverse transcribed into DNA and the viral IN 
enzyme incorporates the viral genome into the host genome (14, 15). Using host machinery, the 
viral genome gets transcribed into mRNA that are then translated into HIV-1 precursor proteins. 
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PR cleaves the polyprotein structures into individual viral proteins and the virus begins to assemble 
at the membrane surface of the host cell (16). After the viral proteins and RNA genome migrate to 
the newly formed particle, the virus buds from the cell in search of a new host cell to infect (17).  
While CD4+ T cells are the primary target of HIV-1, CD4+ T cell depletion is primarily 
caused by programmed cell death of uninfected cells through multiple mechanisms. Monocytes 
undergoing CD4 cross-linking express Fas ligand resulting in CD4+ T cell apoptosis (18). 
Similarly, crosslinking of bound gp120 on the surface of uninfected CD4+ T cells induces cell 
death (19). Further, HIV-1 pathogenesis is driven by viral proteins including Nef. Nef is known to 
contribute to immune evasion by downregulating CD4 and MHC-1 molecules. In addition, Nef 
increases viral replication by activating NF-κB, JNK, and AP-1; transcription factors that bind to 
the HIV-1 long terminal repeat (LTR) leading to viral transcription (20). Finally, chronic immune 
activation contributes to HIV-1 pathogenicity. Chronic immune activation is believed to be due to 
multiple factors including the rapid depletion of CD4+ T cells in the gut disrupting the 
immunological barrier and allowing microbes and microbial products into the lymphatics; a 
phenomenon known as microbial translocation (21). Chronic immune activation may cause 
reduced CD4+ T cell-recovery on antiretrovirals and can contribute to early onset of non-AIDS 
related complications such as cardiovascular disease, and neurocognitive impairment (21-23).  
1.3 Host Genetics and Progression to AIDS 
Like many diseases, HIV-1 disease progression relies on viral pathogenicity as well as 
innate host genetics. Progression to AIDS can vary, and there are several host factors that 
contribute to rapid or slow progression. Many of these genetic factors interact directly with the 
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virus during its life cycle or are a part of the host immune response to the virus. For example, an 
important co-receptor for HIV-1, CCR5, is expressed on the surface of macrophages, dendritic 
cells, and CD4+ T cells and allows for attachment and entry. Individuals who are homozygous for 
the CCR5-Δ32 deletion (1% of the Caucasian population) demonstrate almost complete resistance 
to HIV-1 infection as they lack the co-receptor required for entry (24, 25). Those who are 
heterozygous for the deletion express lower levels of the CCR5 protein and have markedly slower 
progression to AIDS as the virus is unable to disseminate as effectively throughout the body (26).  
As mentioned, variants in the immunological response may also dictate disease 
progression. Antigen presentation proteins called Human Leukocyte Antigen (HLA) are 
responsible for presentation of viral components thereby stimulating a specific and robust immune 
response. Variants in HLA-1 (A-C) receptors such as HLA*B57 are associated with slower 
progression. Individuals expressing HLA*B57 are more likely to present with asymptomatic acute 
HIV-1 infection and control HIV-1 viremia (<5000 copies HIV-1 RNA/mL) in the absence of 
therapy (27). However, variants and homozygosity in HLA types may result in rapid progression; 
such is the case for HLA*B35 (28).  
1.4 Multicenter AIDS Cohort Study Participants 
As previously mentioned, limited information about HIV-1 disease progression can be 
obtained from newly-infected individuals as, due to the advent of powerful and safe antiretroviral 
therapies (ARTs), patiens now commence therapy immediately upon diagnosis. Therefore, in this 
study we utilized retrospective patient samples from the Multicenter AIDS Cohort Study (MACS). 
The MACS is a 30 yearlong study of HIV-1 infection and disease progression in men who have 
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sex with men. Over 7,000 men have participated in the MACS sites of Baltimore, Chicago, 
Pittsburgh, and Los Angeles, and retrospective samples were used based on progression status 
(29). The participants utilized in this study include, Nonprogressors (NPs) (n = 7) and Progressors 
(PRs) (n = 6). NPs maintain low levels of viremia (<2,000 copies/mL) with stable CD4+ T cell 
counts (>500 cells/mm3) over an average of 11 years after seroconversion. PRs had T cell counts 
<500 cells/mm3 over approximately 5 years of infection with persistent viremia (30). NPs and PRs 
were ART naïve upon sample collection and were HLA typed and genotyped for CCR5Δ32. One 
NP but no PRs carried the CCR5Δ32 heterozygous genotype, and no NPs but two PRs, harbored 
the HLA B*5701 allele (30).  
1.5 Cis vs. Trans Infection 
HIV-1 disseminates from cell to cell via two different mechanisms. Cis infection is a 
replication dependent mechanism of transfer where virions produced from one host cell encounter 
another and initiate infection upon gp120/gp41 binding CD4 and CCR5 (31). On the contrary, 
trans infection involves the process of a cell mediated transfer of HIV-1 virions through an 
infectious synapse, and/or exocytosis of exomes carrying HIV-1, independent of viral replication 
(32). Of the antigen presenting cells (APCs) capable of trans infection, dendritic cells (DC) are 
particularly important because of their role linking the innate immune response to the adaptive by 
transfer of antigens to CD4+ helper T cells. Once a dendritic cell encounters HIV-1 in the 
periphery, HIV-1 binds to many C-type lectin receptors on the DC, such as DC-SIGN, via gp120 
and the virus can either “surf” on the surface of the DC until it reaches a CD4+ T cell or become 
internalized and then released in an HIV-1 associated exosome (33).  
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Dendritic cells primarily facilitate trans infection as primary infection of DCs is severely 
limited in vivo (34).  Dendritic cells, monocytes, macrophages, and resting CD4+ T cells express 
SAMHD1, an HIV-1 restriction factor. SAMHD1 is a deoxynucleotide triphosphate (dNTP) 
triphosphohydrolase responsible for limiting the pool of available dNTPs for viral replication (35).  
SAMHD1 and other restriction factors make in vitro infection of DCs limited and with low 
efficiency (36). Despite inefficient infection of DCs during in vitro studies, levels of plasmacytoid 
dendritic cells (pDCs) and myeloid dendritic cells (mDCs) correlate with disease progression 
following antiretroviral therapy (ART), suggesting a continuous disease process affecting DC 
viability regardless of clinical disease progression (37).   
1.6 Epigenetic Regulation of Gene Expression 
A multitude of factors contribute to gene expression and the process is highly complex. 
Among the mechanisms of gene expression, epigenetics refers to heritable variations that are not 
due to sequence level mutations (38). This is possible due to larger genome associated proteins 
called histones that are responsible for packaging DNA into tight bundles. Histones function as an 
octamer, with 2 copies of each histone protein: H2A, H2B, H3, and H4. An octamer of histones 
associated with DNA is referred to as a nucleosome. These epigenetic structures are important for 
gene regulation because they determine which regions of the genome are open and available to 
transcription enzymes such as transcription factors and RNA polymerase (39). Regulation of 
chromatin availability is an intricate process involving chromatin regulators which are further 
classified into histone modifying enzymes and chromatin remodeling proteins. Histone modifying 
enzymes are responsible for post translational modifications of histone tails via acetylation, 
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methylation, phosphorylation, and glycosylation, to name a few. While each modification works 
via a different mechanism, the end results is either open or close regions of chromatin in response 
to various stimuli. Chromatin remodeling proteins differ from histone modifying enzymes in that 
they primarily change the nucleosome structure by moving or removing histone proteins (39, 40). 
Chromatin remodeling proteins will not be further discussed as they are beyond the scope of this 
thesis work. 
While there are many different methods for studying chromatin accessibility, Assay for 
Transposase-Accessible Chromatin (ATAC-Seq) is the only method able to provide a genome-
wide analysis of the chromatin landscape (41). More established methods, including Chromatin 
Immunoprecipitation Sequencing (ChIP-Seq) involve antibody “pull-downs” which enrich for 
specific regions of the genome associated with particular histone modifications. While an effective 
technique, ChIP-seq cannot capture the entire genomic landscape (42).  
ATAC-sequencing provides genome-wide chromatin accessibility data with as little as 
50,000 cells--much less than is required for other genomic assays. The transposition reaction 
involves a modified bacterial enzyme known as transposase that carries sequencing adapters. 
During the reaction the enzyme will bind to open regions of chromatin and insert sequencing 
adapters required for downstream sequencing on Illumina platforms (41).  
Because only sequences with adapters will be compatible with the downstream sequencing 
technology, other closed regions of genomic DNA will not be sequenced.  Finally, data analysis 
involves a process known as “peak-calling” in which reads will be aligned to the reference genome 
and “peaks” will be called when reads consistently align at the same region of the genome (43). 
Peaks, therefore, represent regions that are open and available for transcription.  
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1.7 Genes of Interest 
Rappocciolo et al. extracted total RNA from 9 NPs and 7 PRs and transcript levels were 
analyzed using an Illumina HT-12 BeadChip microarray. The Lumi and Limma software packages 
available in R were used to normalized and analyze the data resulting in the heat map in Figure 1. 
NPs (depicted here as VC, for Viremic Controller) are present underneath the red horizontal header 
and PRs are depicted underneath the blue horizontal header. Genes listed on the right side of the 
heat map were significantly differentially expressed in monocyte-derived DCs with an FDR of q 
< 0.0025. The heat map colors green and red indicate level of transcript expression with red 
indicating downregulation or a decrease in expression and green indicating higher levels of 
expression in a transcriptome-wide comparison of gene expression.  
PALLD, also known as Palladin, was selected for SNP analysis as it showed the greatest 
difference in expression between NPs and PRs with higher expression in NPs, as seen in Figure 1.  
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Figure 1. Differentially expressed genes between MACS NPs and PRs. 
1.7.1  Palladin (PALLD) 
Palladin is a recently characterized cytoskeletal protein involved in countless cytoskeletal 
rearrangements including, cell motility, filopodia formation, and membrane ruffling (44-46). The 
PALLD encodes 9 different isoforms with differential expression depending on cell state and type 
(47). The 90-Kda isoform, also known as isoform 4, binds filamentous actin using immunoglobulin 
domains at the C-terminal end, and binds actin-binding proteins VASP, α-actinin, and Eps8 at the 
N-terminal end (48). Isoform 4 is also the isoform known to be expressed in dendritic cells (49). 
Due to its ability to bind and recruit multiple actin-binding proteins, palladin is considered a 
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cytoskeletal scaffold protein conferring large effects on the cellular cytoskeleton when its 
overexpressed (50). The PALLD gene is about 431kb in length and is located on chromosome 4 
with 3 transcriptional start sites (TSS) (48) .  
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2.0 Statement of Project 
We hypothesize that differential gene expression observed between iDCs from NPs and 
PRs is due to promoter region mutations in PALLD. Further, we believe this differential gene 
regulation, and differences in disease progression may also be due in part to variants in chromatin 
regulators affecting chromatin structure, therefore; we are interested in using the Omni-ATAC-seq 
protocol for chromatin accessibility analysis. For many HIV NPs the mechanism behind disease 
control remains unknown. We aim to determine mechanisms behind differential gene regulation 
through sequencing level and epigenetic analyses.   
2.1 Aim #1 
Determine if there are promoter region mutations in PALLD that are associated with 
progression status. 
2.2 Aim #2 
Validate the use of the Omni-ATAC-seq protocol with healthy donor monocyte-derived 
iDCs.  
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3.0 Research Design 
3.1 Amplicon Sequencing 
Primer sequences to be used in amplicon sequencing of palladin, were generated utilizing 
the Primer3 program implemented in the commercial sequence analysis software, MacVector. 
Gene sequences were uploaded into MacVector from the University of California Santa Cruz 
Genome Browser. Separate primer sets were designed for each exon of PALLD as presented in 
Table 1. Oligonucleotide sequences were provided by Integrated DNA Technologies. PALLD 
amplicons were approximately 5Kb-3Kb in length to capture the promoter region including 
upstream regulatory regions of each transcriptional start site.   
 
Table 1. Primer Sequences for palladin Transcriptional Start Sites 
GENE REGION SEQUENCE 
PALLD Transcriptional Start Site 1 F: TTCAGGATCTCTGATTAACTACC 
R: CAGATTAACAAACCAACACTAGC 
Transcriptional Start Site 2 F: GTAAGGATCTGAAATGTGTCTTAG 
R: ATAAATAGGGAGTACAGCTCTTCG 
Transcriptional Start Site 3 F: CATTTTGAGCTAGATAGTGTCC 
R: AGTTAAAATGAGACAAACGGG 
 
PCR conditions varied depending on amplicon length, and primer annealing temperatures. 
All PCR reactions were performed using Q5 High fidelity 2X Master Mix by New England Biolabs 
and samples were ran in triplicates. PCR conditions for each amplicon are represented in Table 2, 
Table 3, and Table 4. Components of each PCR reaction are found in Table 5.  
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Table 2. PCR Conditions for Transcriptional Start Site 1 of palladin 
 
 
 
 
Table 3. PCR Conditions for Transcriptional Start Site 2 of palladin 
PCR Conditions 
98°C 30 secs 
Then 35 Cycles of: 
98°C 10 secs 
61°C 30 secs 
72°C 3.5 mins 
Followed by 
72°C 3 mins 
 
Table 4. PCR Conditions for Transcriptional Start Site 3 of palladin 
 
 
 
 
  
 
 
 
PCR Conditions 
98°C 30 secs 
Then 35 cycles of:  
98°C 10 secs 
62°C 30 secs 
72°C 5.5 mins 
Followed by: 
72°C 3 mins 
PCR Conditions 
98°C 30 secs 
Then 35 Cycles of: 
98°C 10 secs 
61°C 30 secs 
72°C 5.5 mins 
Followed by: 
72°C 3 mins 
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Table 5. palladin PCR Reaction Components 
Reagent Volume Per Reaction (µL) 
Q5 High-Fidelity Buffer 5 
10 mM dNTPs 0.5 
10 mM Primers 1.25 
Q5 High-Fidelity Polymerase 0.25 
Q5 Enhancer 5 
Nuclease Free Water 11 
 
Following PCR amplification, gel electrophoresis was performed on an 8 µL aliquot of the 
PCR reaction. The PCR reaction was mixed with 2 µL of loading dye and loaded into a 1% agarose 
gel with gel red. Electrophoresis was performed at 100 volts for 30 mins and fragments were 
visualized using a transilluminator. A representative gel electrophoresis image can be found in 
Figure 2.  
 
Figure 2. palladin Transcriptional Start Site 1 Amplicons of 16 NPs, PRs and SN in Triplicate 
 
Amplicons were purified to remove PCR reaction contaminants using AMPure XP beads 
following the manufacturer’s protocol. Briefly, libraries were suspended in 30.6 µL of AMPure 
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XP beads and incubated at room temperature for 5 mins. Libraries were placed on a magnetic rack 
for an addition 5 minutes at room temperature. Supernatant was removed, and bead pellets were 
washed twice with 70% ethanol while on the magnetic rack. Ethanol was removed, and beads were 
dried at room temperature for 3-5 minutes. Samples were removed from the magnetic rack and 
resuspended in 50 µL of 10 mM Tris HCl for 5 mins. Samples were placed back on the magnetic 
rack and supernatant was removed and stored at -20°C. Following purification, samples were 
quantified using Qubit Fluorometer 2.0 and amplicons from each transcriptional start site were 
pooled together resulting in one library of amplicons per individual. Library concentration and 
molarity prior to final pooling during library preparation can be found in Table 6. Molarity was 
calculated using the following equation based on average fragment size as determined by the 
Tapestation 2200 during library preparation: 
�
𝑛𝑛𝑛𝑛µ𝐿𝐿 𝑋𝑋 106�
�660 𝑛𝑛𝑚𝑚𝑚𝑚𝑚𝑚 𝑋𝑋 600 𝑏𝑏𝑏𝑏𝑏𝑏� 
Library preparation was performed using the Illumina Nextera Flex Kit for 24 samples 
following the manufacturer’s protocol. The final library was quantified via Qubit Fluorometer 
prior to loading at 4nM with a 20% PhiX spike following the Denature and Dilute protocol for the 
MiSeq. Sequencing was performed on the Illumina MiSeq provided by the Human Genetics 
Department at the University of Pittsburgh’s Graduate School of Public Health. 
 
 
 
 
 
  16 
 
Table 6. Library Concentration and Molarity for Amplicon Sequencing 
Library Concentration (ng/µL) Molarity 
PR 1 12.5 31.5 
PR 2 13.0 32.8 
PR 3 16.5 41.6 
PR 4 14.3 36.1 
PR 5 12.3 31.1 
NP 1 9.60 24.2 
NP 2 8.90 22.4 
NP 3 11.6 29.5 
NP 4 9.80 24.7 
NP 5 13.1 33.1 
NP 6 13.6 34.3 
NP 7 10.8 27.3 
SN 1 9.54 24.1 
SN 2 12.6 31.8 
SN 3 10.0 25.2 
 
Data analysis was performed on Ubuntu 16.04.4 LTS. Alignment of the fastq files to the 
human hg38 reference genome was performed using BWA mem version 0.7.12-5. SAMtools 
version 0.1.19-1ubuntu1 was used to add coordinates to the mapped reads and index before GATK 
version 4.0.11.0 was used to mark duplicate reads, remove sequencing errors, call variants using 
Haplotype caller, and hard filter variants using parameters as follows: QD > 2, MQ < 40, FS > 60, 
Haploytype score > 13, MQRankSum < -12.5 and ReadPOSRankSum < -8. Joint variant calling 
files (VCF) were compared in Microsoft Excel and variants with distinguishing allele frequencies 
were determined. 
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3.2 TaqMan® Genotyping 
Variants discovered in palladin were subjected to TaqMan based genotyping in a larger 
cohort of MACS participants to determine if allele frequencies observed in our small cohort may 
be replicated in a larger cohort. Using a TaqMan genotyping assay provided by ThermoFisher 
Scientific, 112 NPs and 58 PRs were genotyped following the manufacturer’s protocol as 
described in Table 7. The genotyping assay was functionally tested and able to detect the A/G 
transition substitution variant with VIC (A-allele) and FAM (G- allele) dyes. Allelic discrimination 
plots were generated for each qPCR run (Figure 4). A contingency table was used to determine 
statistical significance when comparing the allele frequency in NP and PR cohorts (Table 9). 
 
Table 7. TaqMan® Genotyping Assay qPCR Components 
Reagent Volume Per Reaction 
(µL) 
TaqMan Genotyping Master Mix 12.5 
20X Assay Working Stock 1.25 
DNA Template 2.5 
 
 
Table 8. TaqMan® Genotyping Assay qPCR Cycling Conditions 
Cycling Conditions 
95°C 10 mins 
The 40 cycles of: 
95°C 15 secs 
60°C 1 min 
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3.3 ATAC-Sequencing Cell Culture 
Healthy donor monocytes were previously isolated using CD14+ selection from Central 
Blood Bank donor AP-001 are were used for ATAC-seq validation. Cells were removed from 
liquid nitrogen and thawed in a 37° water bath for 3 mins before being resuspended in 10 mL of 
complete IMDM media. Cells were pelleted at 1,200 rpm for 5 mins and resuspended in 5 mL of 
complete IMDM media for cell counting via hemocytometer.  Half a million monocytes were then 
plated per well of a 12 well plate with IMDM media and 1,000 IU of IL-4 and GM-CSF for 5 days 
at 37°C. After 5 days iDCs were harvested by washing wells with 1X PBS and cells were counted 
via a hemocytometer.  
3.4 Transposition Reaction 
Triplicates were made of 50,000 cells per transposition reaction and iDCs were treated 
following the Omni-ATAC-seq protocol from Corces et al, 2017. Briefly, cells were incubated 
with 200U/mL of DNase I for 30 mins at 37°C then pelleted and washed with PBS to remove 
residual DNase. Cells were then resuspended in 50 µL of ATAC-Resuspension Buffer (RSB) 
containing 0.1% NP40, 0.1% Tween-20, and 0.01% Digitonin. After a 3 min incubation on ice, 
cells were resuspended in 1 mL of ATAC-RSB containing 0.1% Tween-20 and the tubes was 
inverted to mix. Nuclei were pelleted at 500 RCF for 10 mins at 4°C and ATAC-RSB was 
removed. Pellets were then resuspended in 50 µL of transposition mixture containing 2X TD 
buffer, transposase, PBS, 1% digitonin, 10% Tween-20, and nuclease free water. The reaction was 
incubated at 37°C for 30 mins in a thermomixer at 1000 RPM. DNA resulting from the 
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transposition reaction was purified using the Zymo DNA Clean and Concentrator-5 kit following 
the manufacturer protocol. DNA was stored at -20°C until amplification. An aliquot from each 
library was taken for fragment analysis via the Tapestation 2200. Concentrations from Tapestation 
2200 analysis prior to library amplification are provided in Table 9.  
 
Table 9. Library Concentrations via Tapestation 2200 
ATAC-seq Library Concentration (pg/µL) 
ATAC 1 21300 
ATAC 2 1150 
ATAC 3 765 
 
3.5 ATAC Library Preparation and Sequencing  
Libraries were amplified using 2X NEBNext Master Mix, as outlined in Table 10, and 
Illumina primer sequences with barcode indexes were used for multiplexing as seen in Table 11, 
Table 12, and Table 13. PCR conditions were as follows: 72°C for 5 mins, 98°C for 30 sec, then 
5 cycles of 98°C for 10 sec, 63°C for 30 sec, and 72°C for 1 min. Reactions were then stored on 
ice while 5 µL was taken for qPCR amplification to determine the additional number of cycles 
required for complete library amplification. The 5µL aliquot of each library was amplified as 
follows: 98°C for 30 sec, then 35 cycles of 98°C for 10 sec, 63°C for 30 sec, and 72°C for 1 min. 
Reagents for the qPCR can be found in Table 7. Plotting RN vs. cycles, we determined which 
cycle yielded ¼ of total fluorescence intensity and amplified the libraries for an additional 11 
cycles. Following amplification libraries were purified using Agencourt AMPure XP beads 
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following the size selection protocol by the Kaestner Lab at the University of Pennsylvania to 
remove fragments greater than 1000 bps.   
 
Table 10. Pre-Amplification PCR Master Mix 
Reagent Per Reaction (µL) 
25µM Primer i7 2.5 
25µM Primer i5 2.5 
2X NEBNext Master Mix 25 
DNA Template 20 
 
Table 11. Nextera Index Kit PCR Primers 
Index 1 Read CCAAGCAGAAGACGGCATACGAGAT[i7]GTCTCGTGGGCTCGG 
Index 2 Read AATGATACGGCGACCACCGAGATCTACAC[i5]TTCGTCGGCAGCGTC 
 
Table 12. Nextera Index Kit Index 1 (i7) Adapter 
i7 Index Name Bases in Adapter 
N701 TCGCCTTA 
 
 
Table 13. Nextera Index Kit Index 2 (i5) Adapters 
i5 Index Name Bases in Adapter 
N502 CTCTCTAT 
N503 TATCCTCT 
N505 GTAAGGAG 
 
Table 14. Reagents for qPCR to Determine Additional Cycles 
Reagent Per Reaction (µL) 
Primer i7 3.76 
Primer i5 0.5 
25X SYBR Green 0.5 
2X NEBNext Master Mix 0.24 
Water 5 
DNA Template 5 
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Libraries were sequenced on an Illumina NextSeq 550 sequencer, at the University of 
Pittsburgh Genomics Research Core, at concentration of 1.6pM using 2 x 76 cycles paired end 
with PhiX spiked in at 1%.   
3.6 ATAC-Sequencing Data Analysis 
Alignment of FastQ files was performed using the human reference genome hg19 and the 
latest version of BWA as of March 2018. SAMtools was used to fix and sort the genome based on 
gene coordinates and ATAC-seqQC version 3.8 in R was used for library coverage and quality 
analysis. 
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4.0 Results 
4.1 rs6820223 in palladin is Present in All NPs and Absent in PRs 
Palladin promoter region analysis revealed that SNP rs6820223 (A/G) located near the 
third transcriptional start site had an allele frequency of 0.929 in NPs but was completely absent 
from PRs. Allele frequency describes the number of chromosomes in the cohort that possessed the 
variant, meaning; 6 NPs were (AA) homozygous while 1 NP was (AG) heterozygous. A 
representative image from the Integrative Genomic Viewer (IGV) depicts homozygosity of rs 
6820223 in NP 4 represented as an orange line throughout the read depth at position 168,832, 569 
(Figure 3). rs6820223 is present in the RB1 transcription factor binding site near the isoform 4 
promoter region of palladin; the known isoform to be expressed in iDCs (49).  
 
Figure 3. Representative IGV Image of NP 4 Near Transcriptional Start Site 3 
 
  23 
4.2 palladin Variant is in the RB1 Transcription Factor Binding Site Near Isoform 4 
Promoter Region 
As mentioned, palladin possesses three alternative transcriptional start sites and expression 
is dependent on cell type and state. rs6820223 is located near the promoter region of the third 
transcriptional start site in the Retinoblastoma Protein 1 (RB1) binding site. RB1 is a tumor 
suppressor gene important for regulation of cell cycle and stabilization of heterochromatin.   
4.3 rs6820223 Allele Frequency Was Not Replicated in a Larger MACS Cohort 
Genotyping of SNP rs6820223 was performed using a commercially available TaqMan 
based genotyping kit provided by ThermoFisher Scientific. Using a probe-based design, the 
TaqMan assay determined the genotype at chromosome position 168,832,569 in a larger MACS 
cohort of 112 NPs and 58 PRs. Allelic discrimination plots were generated per qPCR run as seen 
in Figure 4. Odds ratios and p-values were calculated using a contingency table as seen in Table 
15.  Based from the contingency table, there is no statistically significant difference of the AA 
genotype between NPs and PRs (OD 0.96, p-value 0.94).  
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Figure 4. Allelic Discrimination Plots from rs6820223 Genotyping Assay 
 
Table 15. Allele Frequency Table of palladin rs6820223 in NPs and PRs 
 NP PR 
GG 54 26 
GA 46 26 
AA 12 6 
 
4.4 ATAC-Sequencing Library Complexity and Mapping 
ATAC-sequencing was performed on previously isolated monocytes from healthy donor 
AP-001 in triplicate. Libraries generated from iDCs had comparable quality metrics displayed in 
table 16. Percent proper pair describes the percentage of paired end reads that properly align, 
percent mapped describes the number of reads that were mappable to the human reference genome 
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hg19, mitochondrial rate describes the number of reads that mapped to the mitochondrial genome, 
and the PCR Bottleneck Coefficient conveys library complexity. A representative image of 
ATAC1 read fragment size is presented in Figure 6. Fragment sizes range from <100 bps to 
approximately 300bps with the large majority around 200 bps in length. As seen in the normalized 
read density plot, reads demonstrate periodicity with fragment sizes trailing after 300 bps.  
 
Table 16. Summary Statistics of the 3 ATAC-seq Libraries 
 % Mapped Mitochondrial Rate Proper Pair Rate PCR Bottleneck Coefficient 
ATAC1 99.63 0.0098 0.965 3.87 
ATAC2 99.62 0.0250 0.966 2.90 
ATAC3 99.57 0.0446 0.974 2.85 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 5. Distribution of Library Complexity as a QQ-Plot 
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Figure 6. Fragment Size Distribution of ATAC Libraries 
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5.0  Discussion 
Since the 1990s, HIV-1 treatment and outcomes have vastly improved with the advent of 
combined antiretroviral therapies. Yet, in the early years of HIV-1 infection it became clear that 
progression to AIDS was not uniform in the HIV-1 infected population. Individuals known as 
progressors represented the typical rate to AIDS progression while a smaller group now known as 
nonprogressors were able to maintain stable CD4+ T cell counts with varying levels of viral load 
in the absence of therapy. Recent studies have shown that a select group of MACS nonprogressors 
possess iDCs that are inherently unable to trans infect CD4+ T cells. Understanding underlying 
variants and epigenetic contributions to the HIV-1 response may uncover novel mechanisms of 
control to be applied to HIV-1 treatment, and possibly to viral infections broadly.   
5.1 Transcriptome Analysis Determines Palladin Expression in Nonprogressors with 
Inefficient Trans Infection is Significantly Higher than in Progressors 
Recent studies completed by Rappocciolo et. al determined that a select group of MACS 
cohort nonprogressors were unable to disseminate HIV-1 via trans infection of CD4+ T cells in 
vitro. These nonprogressors are not homozygous for the CCR5-Δ32 mutation, nor do they possess 
the HLA-B57 subtype. Because this select group of nonprogressors did not possess the known 
causes of non-progression, it is possible these individuals control their HIV-1 infection through 
novel mechanisms. HT-12 microarray data obtained by Rappocciolo et al, revealed that palladin 
expression was significantly upregulated in the nonprogressor cohort with a p-value < 0.0025 as 
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presented in Figure 1. It is important to note that due to the 3’ IVT probe detection design of the 
HT-12 microarray, it was not able to discern which palladin isoform was overexpressed in the 
nonprogressors. Due to this limitation, amplicon sequencing was performed on each transcriptional 
start site to identify variants that may impact the numerous Palladin isoforms leading to 
overexpression. 
5.1.1  Palladin is a Cytoskeletal Scaffold Protein with Drastic Effects on Cellular Function 
Previous studies have described palladin as a cytoskeletal scaffold protein essential for 
numerous rearrangements including filopodia, membrane ruffles, and stress fiber formations 
depending on the cell type (48). Of the nine different isoforms it was determined that iDCs 
primarily expression isoform 4 which stems from the third transcriptional start site of palladin 
(44). While many studies have conflicting conclusions on the primary role palladin plays, it is 
clear, among other cytoskeleton proteins that concentration within the cell is delicate and tightly 
controlled. Palladin overexpression and knockdown has significant impact on normal cellular 
functions. For example, overexpression of palladin within the context of cancer increases cellular 
motility, while palladin overexpression can also contribute to cell rigidity via the strengthening of 
stress fibers(47, 51). Interestingly, Zaccard et al. recently determined that tunneling nanotubes 
(TNTs) potentially act as an effective mechanism of trans infection from type-1 polarized dendritic 
cells to CD4+ T cells in vitro (52). Tunneling nanotubes are cytoskeletal projections that connect 
DCs to T cells upon CD40L stimulation (52). While palladin remains an understudied protein, it 
is feasible to consider the impact of palladin overexpression on the ability to form TNTs and 
effectively trans infect.  
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5.2 Amplicon Sequencing Detects Variant in the Third TSS of palladin with a High Allele 
Frequency in NPs 
Amplicon sequencing of the three PALLD transcriptional start sites revealed variant 
rs6820223 near the third TSS of palladin with an allele frequency of 0.929 in the NP cohort, and 
0 in the PR cohort. Allele frequency describes the number of chromosomes within the cohort that 
possess the variant; meaning all but one NP were homozygous for the variant and the variant was 
not present in the PR cohort. The variant is located in the binding site for RB1, a known 
transcription factor important for controlling heterochromatin structure for gene expression. As 
previously mentioned, iDCs primarily express isoform 4 which originates from the third TSS so it 
is possible rs6820223 disrupts RB1 binding leading to increased expression of isoform 4. Further 
studies into the impacts of chromatin structure on gene expression in HIV NP and PR cohorts will 
be needed to determine the functional impact of epigenetic influences on HIV-1 disease 
progression.  
5.3 Allele Frequency of rs6820223 in Modest Cohort was not Replicated in a Larger Cohort 
Analysis 
Genotyping of rs6820223 was performed in a larger MACS cohort consisting of 112 NPs 
and 58 PRs using a Taqman probe-based assay. Genotyping revealed that rs6820223 was not 
enriched in the NP cohort as seen in the small cohort that was used for amplicon sequencing. While 
it is possible rs6820223 is not associated with progression status, it is also possible that the cohort 
of 112 NPs possess other genetic causes of nonprogression. A heterogenous cohort of NPs can 
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reduce the signal of an association between rs6820223 and nonprogression. A larger cohort of NPs 
must be assayed for trans-presentation capability, palladin expression, cellular cholesterol content 
and, genotyped for rs6820223 to fully investigate the relationship. As for many genetic association 
studies, a genetically heterogenous population can be problematic for detecting true associations 
between genotype and phenotype therefore; researchers must make efforts to carefully classify and 
group cohorts based on phenotypes such as palladin expression, and cholesterol content. 
5.4 The Omni-ATAC-Sequencing Method Successfully Removes Mitochondrial 
Contamination and can be Used to Determine Chromatin Accessibility in NPs and PRs 
Assay for transposase accessible chromatin (ATAC) sequencing is a relatively new method 
to determine open regions of chromatin from cells or a cell line of choice. Similar to ChIP-
sequencing, ATAC-seq results in sequencing reads aligning to a whole reference genome with 
sequencing depth determining regions called “peaks”. Peaks are regions of chromatin that were 
accessible by the transposase enzyme to adhere sequencing adapters and are therefore considered 
open and available for transcription. The Omni-ATAC-sequencing protocol published by Corces 
et al. provides a modified ATAC-seq protocol that may be used on a wide range of cell types and 
allows for improved signal-to-background ratio. The protocol includes cell/nucleus washes in 
Digitionin, Tween 20, and NP40 as well as a DNase step to remove DNA from non-viable cells.  
The protocol was applied to iDCs differentiated from healthy donor monocytes to 
determine if the protocol could be used on MACS retrospective NP and PR samples. ATAC-
sequencing was chosen over other chromatin assays because it allows for as little as 25,000 cells 
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as input and can reveal the genome-wide chromatin landscape as opposed to ChIP-sequencing 
which requires specific regions to be “pulled-down”.  
The Omni-ATAC-seq protocol was followed as stated in Corces et al, utilizing the DNase 
step to improve signal-to-background ratio, and Illumina Nextera XT adapters were used for 
library preparation as stated in Table 11, Table 12, and Table 13. Following sequencing from the 
Genomic Core Labs at the University of Pittsburgh, reads were aligned to the hg19 reference 
genome using BWA and sorted and indexed using SAMTools before being loaded into 
ATACseqQC. ATACseqQC is an R/Bioconductor program used to assess library complexity and 
quality from ATAC-sequencing protocols. Proper library complexity and quality indicates a 
successful sequencing experiment. Because our data were obtained from triplicate preparations 
from one donor, we do not expect to see differences between them, other than what might be due 
to technical variation in sample processing.  
The ATACseqQC program was used to generate summary statistics for each library as 
provided in Table 16. Of importance, mitochondrial reads were vastly depleted using the Omni-
ATAC-seq protocol in all libraries. Similarly, the percent of reads mapped was significantly high 
for each library indicating a successful sequencing run. The PCR bottleneck coefficient determines 
how skewed the data is based on read counts across the genome, and while the distribution is 
slightly skewed from normal as seen in Figure 5, sequencing depth was sufficient across the 
genome. Further, the ENCODE ATAC-sequencing data quality standards indicate that each library 
should contain approximately 50-million reads for paired end sequencing and 2 out of the 3 
libraries had greater than 60-million reads, while ATAC library 1 was comparable with 47-million 
reads. Another important parameter for ATAC-sequencing data is fragment size distribution as 
shown in Figure 6. Fragment sizes for a successful ATAC-seq run are typically between 50-1,000 
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bps with a decline in density as the fragments get larger. Per Corces et al, 2018, ATAC-seq libraries 
with a fragment distribution similar to Figure 6 are typically displaying biased size selection during 
library preparation. Moving forward, the AMPure Bead size selection protocol should be modified 
to remove bias and improve the concentration of reads less than 100 bps and greater than 300 bps.  
5.5 Experimental Limitations 
As with many experiments, the most relevant cell types are not always available due to cell 
availability limitations. Monocyte-derived immature dendritic cells behave similarly to in vivo 
immature dendritic cells however, it is important to note that the majority of in vivo immature 
dendritic cells are not monocyte-derived. Therefore, inconsistencies may exist between our in vitro 
results and what may be occurring in vivo. Immature dendritic cells were chosen for study to be 
consistent with the HT-12 microarray data from Figure 1 which was completed on MACS iDCs.  
5.6 Conclusion and Future Directions 
Understanding how innate host genetics contributes to disease progression is important for 
a plethora of infectious diseases. More importantly, genetic characteristics associated with slower 
or faster disease progression may not always lie in immunological pathways. Discovery tools such 
as transcriptome analysis, and chromatin accessibility performed on small, and highly 
characterized cohorts may reveal nonintuitive mechanisms of disease control in need of further 
investigation. Palladin is a novel gene in HIV progression studies and overexpression of palladin 
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in our cohort of NPs warrants an investigation of palladin expression in a larger cohort. Such NPs 
with high palladin expression may then be genotyped for rs6820223 to investigate an association. 
Additionally, given palladin’s role in cytoskeletal rearrangements, immunohistochemistry of 
palladin expression during iDC differentiation and activation may inform its role in general 
function and TNT development. Secondly, ATAC-seq performed in MACS NP and PR iDCs will 
reveal inherent differences in chromatin structure that may present new avenues of investigation.     
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